Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Deferring a Change in the Standard of Care for Small Cell Lung Cancer Brain Metastases

Deferring a Change in the Standard of Care for Small Cell Lung Cancer Brain Metastases Letters Administrative, technical, or material support: Morrison, Stetler-Stevenson, cifically examined. The ability of models to classify patients Kazandjian. as HR vs non-HR was significantly different (Figure, B). Supervision: Landgren, Kazandjian. Other—rendering diagnoses for the patients described in this study: Yuan. Discussion | The accurate identification of patients with SMM Conflict of Interest Disclosures: Dr Landgren reported receiving research at highest risk of developing MM remains difficult. While the funding and consultancy fees from Janssen, Amgen, Celgene, Takeda, Novartis, US Food and Drug Administration, Multiple Myeloma Research Foundation, 2018 Mayo Clinic model has a higher concordance rate with International Myeloma Foundation, Leukemia and Lymphoma Society, the PETHEMA model, it remains significantly discordant. Fur- Perelman Family Foundation, Rising Tide Foundation, Glenmark, and Seattle thermore, these models are limited because they do not in- Genetics; receiving consultancy fees from Pfizer, Karyopharm Therapeutics, corporate sensitive imaging techniques, such as positron emis- Adaptive Biotechnologies, the Binding Site, Bristol Myers Squibb, Cellectis, and Juno; receiving honoraria from Medscape; serving on an advisory committee for sion tomography–integrated computed tomography, which can Merck; and serving on an independent data monitoring committee for Takeda, aid in risk stratifying patients who are at highest risk of devel- Janssen, and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Deferring a Change in the Standard of Care for Small Cell Lung Cancer Brain Metastases

JAMA Oncology , Volume 7 (1) – Jan 12, 2021

Loading next page...
 
/lp/american-medical-association/deferring-a-change-in-the-standard-of-care-for-small-cell-lung-cancer-b3S02QBDWv
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.5466
Publisher site
See Article on Publisher Site

Abstract

Letters Administrative, technical, or material support: Morrison, Stetler-Stevenson, cifically examined. The ability of models to classify patients Kazandjian. as HR vs non-HR was significantly different (Figure, B). Supervision: Landgren, Kazandjian. Other—rendering diagnoses for the patients described in this study: Yuan. Discussion | The accurate identification of patients with SMM Conflict of Interest Disclosures: Dr Landgren reported receiving research at highest risk of developing MM remains difficult. While the funding and consultancy fees from Janssen, Amgen, Celgene, Takeda, Novartis, US Food and Drug Administration, Multiple Myeloma Research Foundation, 2018 Mayo Clinic model has a higher concordance rate with International Myeloma Foundation, Leukemia and Lymphoma Society, the PETHEMA model, it remains significantly discordant. Fur- Perelman Family Foundation, Rising Tide Foundation, Glenmark, and Seattle thermore, these models are limited because they do not in- Genetics; receiving consultancy fees from Pfizer, Karyopharm Therapeutics, corporate sensitive imaging techniques, such as positron emis- Adaptive Biotechnologies, the Binding Site, Bristol Myers Squibb, Cellectis, and Juno; receiving honoraria from Medscape; serving on an advisory committee for sion tomography–integrated computed tomography, which can Merck; and serving on an independent data monitoring committee for Takeda, aid in risk stratifying patients who are at highest risk of devel- Janssen, and

Journal

JAMA OncologyAmerican Medical Association

Published: Jan 12, 2021

References